Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 2/20 | 0.38 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | RARG | P13631 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MYC | P01106 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175644 | 0.90 | HDAC1 (0.39) | HDAC1HDAC6NOTUMPOLBMEN1 | |
| SCHEMBL20173810 | 0.78 | ALDH1A1 (0.51) | MCL1HDAC1HDAC6RARARARB | |
| SCHEMBL6297902 | 0.77 | RARA (0.46) | MCL1HDAC1HDAC6RARARARB | |
| SCHEMBL20178668 | 0.73 | ALDH1A1 (0.51) | HDAC1HDAC6RARARARBRARG | |
| SCHEMBL7670996 | 0.72 | HDAC1 (0.49) | HDAC1HDAC6RARARARBRARG | |
| SCHEMBL20173808 | 0.71 | RARA (0.47) | MCL1HDAC1HDAC6RARARARB | |
| SCHEMBL7675774 | 0.69 | HDAC1 (0.44) | MCL1HDAC1HDAC6RARARARB | |
| SCHEMBL17806216 | 0.69 | NOTUM (0.42) | HDAC1HDAC6NOTUMHTTL3MBTL1 | |
| SCHEMBL7675768 | 0.69 | HDAC1 (0.44) | MCL1HDAC1HDAC6RARARARB | |
| SCHEMBL7675776 | 0.69 | HDAC1 (0.44) | MCL1HDAC1HDAC6RARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559709-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | Eisai Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-0838453-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| US-6884808-B2 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6630463-B2 | Such as 4-(4-(2-(2-(5,6,7,8-tetrahydro-5,5,8,8 -tetramethylquinoxalyl))pyrrolyl))benzoic acid; for treatment of acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6541474-B2 | Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-03-14 | — | — | US | disclosed |
| US-6329402-B1 | FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA | EISAI CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-5977108-A | LEUKEMIA | EISAI CO., LTD (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0838453-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | MCL1 834/4885HDAC1 686/4885HDAC6 2604/4885 |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | MCL1 918/4885HDAC1 708/4885HDAC6 2570/4885 |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | MCL1 918/4885HDAC1 708/4885HDAC6 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.